GSK COX-2 Data Show No Short-Term Cardiovascular Risk, Company Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II agent has a safety profile similar to that of Celebrex but offers an “incremental” efficacy benefit over Pfizer’s drug, GSK says. NDA filing is tentatively scheduled for late 2006, but timing may depend on outcome of the Feb. 16-17 FDA advisory committee meeting on COX-2 safety issues.